Celcuity
Preço: 88.55Empresa e modelo de negócios
Celcuity is a healthcare company focused on developing innovative cancer therapies. Its core product is the Celcuity platform, which utilizes a proprietary technology to identify and target specific cancer cell types. The company primarily operates in the oncology segment, generating revenue through partnerships and collaborations with pharmaceutical companies for drug development and clinical trials.
Perfil de investimento
The investment profile of Celcuity is more aligned with growth investors, given its focus on developing new therapies and potential market expansion. The company does not currently offer dividends, and its financial performance indicates a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, with moderate liquidity reflecting the stock's trading characteristics.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- -3.89 Risco
- Surpresa de EPS
- 9.3% melhor que o esperado
- Volatilidade 20d
- 6.5% normal
Impacto da previsão
negativoAcompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-03 02:36 | Manter | Vender | scenario_deterioration |
| 2026-05-08 15:34 | — | Manter | Weak fundamentals with high volatility and uncertain market signals. |
| 2026-05-05 02:37 | — | Manter | Компания демонстрирует значительный рост цен за последние месяцы, что указывает на позитивные ожидания рынка. Однако отрицательный EPS и высокая волатильность требуют осторожности. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-06-03 12:48 | Craig-Hallum | Preço-alvo reduzido | 189 → 171 | 89.1199 |
| 2026-06-03 10:07 | H.C. Wainwright | Preço-alvo reduzido | 185 → 145 | 91.42 |
| 2026-06-03 09:28 | Wells Fargo | Preço-alvo reduzido | — → 166 | 91.42 |
Nada ainda